Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Fut, take a shot at this one please...

All,

I believe I made a mistake in stating that S&L each have 9.99% when they actually beneficially own 9.99% combined. Sorry for the slip up but on the 13G filed previously it looks otherwise especially if you skimmed the document.

Amount beneficially owned:

Lincoln Ventures, LLC - 30,167,239*

Swartz Private Equity, LLC - 30,167,239*

* Assuming that the Issuer had 304,719,593 shares issued and outstanding as of February 9, 2006, which is the number indicated by a certified statement from the Issuer’s transfer agent, Interwest Transfer Company, Inc, then Lincoln Ventures, LLC (“Lincoln”) and Swartz Private Equity, LLC (“SPE”) have beneficial ownership of the above number of shares of common stock. Lincoln and Swartz each hold Warrants to purchase common stock of the company. The documents governing the terms of the Warrants contain a provision prohibiting Lincoln and SPE, as applicable, from exercising warrants for shares of Common Stock if doing so would result in the Reporting Persons and their affiliates beneficially owning shares of Common Stock that represent more than 9.99% of the outstanding shares of Common Stock as determined under Section 13(d) of the Securities Exchange Act of 1934. As a result, the Reporting Persons did not beneficially own more than 9.99% of the outstanding Common Stock. This number assumes that Lincoln Ventures, LLC and Swartz Private Equity, LLC may be deemed to be affiliated and under common control.

(b)

Percent of class:

Lincoln Ventures, LLC - 9.99% (*)

Swartz Private Equity, LLC - 9.99% (*)

(*) see note in 4(a) above.


Dec 08, 2006 12:06PM

Dec 09, 2006 04:37AM

Dec 09, 2006 05:08AM

Dec 09, 2006 07:18AM

Dec 09, 2006 09:22AM

Dec 09, 2006 10:07AM

Dec 09, 2006 11:44AM
Share
New Message
Please login to post a reply